Axis Bank Regulatory Approval

Employee Stock Options

Axis Bank Employee Stock Options

Axis Bank allotted 47,781 equity shares under its ESOP/RSU scheme. This allotment increases the bank's paid-up share capital.

Earnings Call

Axis Bank Earnings Call Transcript: Key Takeaways

Axis Bank delivered robust credit growth and asset quality, though margins were optically compressed by FCNR deposit mobilization.

Management Change

Axis Bank Management Change

Axis Bank has appointed Rahul Shukla as Group Head, Commercial and Bharat Banking, effective October 19, 2026. He will join the Bank's Senior Management team.

Other Announcement

Axis Bank Other Announcement

Axis Bank reported no fund-raising activities or deviations in the use of issue proceeds for the quarter ended September 30, 2026, as per SEBI regulations.

Results Update

Axis Bank Results Update

Axis Bank released its financial results highlights for the quarter ended September 30, 2026, reporting growth in deposits, advances, and net profit.

Financial Results

Axis Bank Q2 FY27 Results: Net Profit ₹7,705 Cr, Up 39.4% YoY

Axis Bank Ltd reported revenue from operations of ₹38,088 Cr (+17.9% YoY) and net profit of ₹7,705 Cr (+39.4% YoY) for Q2 FY27.

Key figure

Net profit ₹7,705 Cr · +39.4% YoY

Regulatory ApprovalShalby Ltd SHALBYAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Shalby Regulatory Approval

Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.

Regulatory ApprovalElantas Beck India Ltd ELANTASAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Elantas Beck India Regulatory Approval

Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.

Regulatory ApprovalKalyani Cast-Tech Ltd 544023Alfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Kalyani Cast-Tech Regulatory Approval

Kalyani Cast-Tech received RDSO Stage-I concept design approval for its new container-carrying wagon under PWDA. Stage-II detailed design approval is still required, subject to dynamics simulation conditions.

Regulatory ApprovalMukka Proteins Ltd MUKKAAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Mukka Proteins Regulatory Approval

Mukka Proteins received a US FDA facility registration certificate, valid October 1, 2026 to December 31, 2027. The company says the registration supports its engagement with US customers and markets.

Execution

October 1, 2026 to December 31, 2027

Regulatory ApprovalCanara Bank CANBKAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Canara Bank Regulatory Approval

Canara Bank received RBI permission to exercise the call option on its Basel III AT1 bonds (ISIN INE476A08134) of Rs.1,500 Crore. The bank is now in process of exercising the call as per the issue terms.

Value

₹1,500 Cr

Regulatory ApprovalAlembic Pharmaceuticals Ltd APLLTDAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Alembic Pharmaceuticals Regulatory Approval

Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. This adds to its cumulative 247 USFDA ANDA approvals.